Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 1;12(7):1752.
doi: 10.3390/cancers12071752.

Immunotherapy in Prostate Cancer

Emily K Fay  1 , Julie N Graff  1   2
Affiliations
Review

Immunotherapy in Prostate Cancer

Emily K Fay et al. Cancers (Basel). .

Abstract

Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have shown impressive responses to cellular and immunotherapy. This review summarizes the current data for immunotherapy's use in prostate cancer, as well as how currently available data might help predict patient responses to immunotherapy. Specifically, we will review vaccine-based therapies, immune checkpoint inhibitors, and future directions that are actively being explored.

Keywords: checkpoint inhibitor; immunotherapy; prostate cancer; vaccine.

PubMed Disclaimer

Conflict of interest statement

E.K.F. has no conflicts of interest; J.N.G. has institutional research funding from Merck, Janssen, Sanofi, Astellas.

References

    1. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn J.C., DeMarzo A.M., Meeker A.K., Isaacs W.B., Drake C.G. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. Clin. Cancer Res. 2008;14:3254–3261. doi: 10.1158/1078-0432.CCR-07-5164. - DOI - PMC - PubMed
    1. Prokhnevska N., Emerson D.A., Kissick H.T., Redmond W.L. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy. Adv. Exp. Med. Biol. 2019;1210:121–147. - PubMed
    1. Drake C.G., Doody A.D.H., Mihalyo M.A., Huang C., Kelleher E., Ravi S., Hipkiss E.L., Flies D.B., Kennedy E.P., Long M., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–249. doi: 10.1016/j.ccr.2005.01.027. - DOI - PMC - PubMed
    1. Mercader M., Bodner B.K., Moser M.T., Kwon P.S., Manecke R.G., Ellis T.M., Wojcik E.M., Yang D., Flanigan R.C., Waters W.B., et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. USA. 2001;98:14565–14570. doi: 10.1073/pnas.251140998. - DOI - PMC - PubMed
    1. Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., Enot D.P., Engblom C., Pittet M.J., Schlitzer A., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–976. doi: 10.1126/science.1240537. - DOI - PMC - PubMed

LinkOut - more resources